Metastasis-inducing Mts1/S100A4 protein binds to tumor suppressor p53 protein

Russian Journal of Genetics

Volumn 39, Issue 7, 2003, Pages 748-755

  Grigorian, M ^a   Lukanidin, E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; PROTEIN P53; PROTEIN S100A4; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REPORTER GENE;

ANIMALIA;

EID: 9344219926     PISSN: 10227954     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024744802324     Document Type: Article

References (47)

1. 2+-Binding Protein Family, Genes Dev., 1989, vol. 3, pp. 10886-10893.
2. Lukanidin, E. and Georgiev, G.P., Metastasis-Related mts1 Gene, Current Topics in Microbiology and Immunology: Attempts to Understand Metastasis Formation, Berlin: Springer-Verlag, 1996, vol. 213, pp. 171-195.
3. Zimmer, D.B., Cornwall, E.H., Landar, A., and Song, W., The S100 Protein Family: History, Function, and Expression, Brain Res. Bull., 1995, vol. 37, pp. 417-429.
4. Takenaga, K., Nakamura, Y., Sakiyama, S., et al., Binding of PEL98 Protein, an S100-Related Calcium-Binding Protein, to Nonmuscle Tropomyosin, J. Cell Biol., 1994, vol. 124, pp. 757-768.
5. Watanabe, Y., Usada, N., Minami, H., et al., Calvasculin, as a Factor Affecting the Microfilament Assemblies in Rat Fibroblasts Transfected by src Gene, FEBS Lett., 1993, vol. 324, pp. 51-55.
6. Kriajevska, M.V., Cardenas, M.N., Grigorian, M.S., et al., Non-Muscle Myosin Heavy Chain as a Possible Target for Protein Encoded by Metastasis-Related mts-1 Gene, J. Biol. Chem., 1994, vol. 269, pp. 19 679-19 682.
7. Kriajevska, M., Tarabykina, S., Bronstein, I., et al., Metastasis-Associated Mts1 (S100A4) Protein Modulates Protein Kinase C Phosphorylation of the Heavy Chain of Nonmuscle Myosin, J. Biol. Chem., 1998, vol. 273, pp. 9852-9856.
8. Levine, A.J., p53, the Cellular Gatekeeper for Growth and Division, Cell (Cambridge, Mass.), 1997, vol. 88, pp. 323-331.
9. Ko, L.J. and Prives, C., p53: Puzzle and Paradigm, Genes Dev., 1996, vol. 10, pp. 1054-1072.
10. Jayaraman, L. and Prives, C., Covalent and Noncovalent Modifiers of the p53 Protein, Cell Mol. Life Sci., 1999, vol. 55, pp. 76-87.
11. Hupp, T.R., Regulation of p53 Protein Function through Alterations in Protein-Folding Pathways, Cell. Mol. Life Sci., 1999, vol. 55, pp. 88-95.
12. Kustikova, O., Kramerov, D., Grigorian, M., et al., Fra-1 Induces Morphological Transformation and Increases In Vitro Invasiveness and Motility of Epithelioid Adenocarcinoma Cells, Mol. Cell. Biol., 1998, vol. 18, pp. 7095-7105.
13. Platt-Higgins, A.M., Renshaw, C., West, C.R., et al., Comparison of the Metastasis-Inducing Protein S100A4 (p9ka) with Other Prognostic Markers in Human Breast Cancer, Int. J. Cancer, 2000, vol. 89, pp. 198-208.
14. Rudland, P.S., Platt-Higgins, A., Renshaw, C., et al., Prognostic Significance of the Metastasis-Inducing Protein S100A4 (p9Ka) in Human Breast Cancer, Cancer Res., 2000, vol. 60, pp. 1595-1603.
15. Coleman, W.B., Grisham, J.W., and Smith, G.J., Morphologic Transformation of the C3H 10T1/2 Cell Line Is Accompanied by Altered Expression of the p53 Tumor Suppressor Gene, Carcinogenesis, 1994, vol. 15, pp. 145-152.
16. Sengupta, S., Vonesch, J.L., Waltzinger, C., et al., Negative Cross-Talk between p53 and the Glucocorticoid Receptor and Its Role in Neuroblastoma Cells, EMBO J., 2000, vol. 19, pp. 6051-6064.
17. Oren, M. and Prives, C., p53: Upstream, Downstream and Off Stream: Review of the 8th p53 Workshop (Dundee, July 5-9, 1996), Biochim. Biophys. Acta, 1996, vol. 9, no. 3, pp. R13-R19.
18. Mundt, M., Hupp, T., Fritsche, M., et al., Protein Interactions at the Carboxyl Terminus of p53 Result in the Induction of Its In Vitro Transactivation Potential, Oncogene, 1997, vol. 15, pp. 237-244.
19. Hupp, T.R., Meek, D.W., Midgley, C.A., and Lane, D.P., Regulation of the Specific DNA Binding Function of p53, Cell (Cambridge, Mass.), 1992, vol. 71, pp. 875-886.
20. Scotto, C., Delphin, C., Deloulme, J.C., and Baudier, J., Mol. Cell. Biol., 1999, vol. 19, pp. 7168-7180.
21. Rust, R.R., Baldisseri, D.M., and Weber, D.J., Structure of the Negative Regulatory Domain of p53 Bound to S100B(ββ), Nat. Struct. Biol., 2000, vol. 7, pp. 570-574.
22. Roberts, D.D., Regulation of Tumor Growth and Metastasis by Thrombospondin-1, FASEB J., 1996, vol. 10, pp. 1183-1191.
23. Ambartsumian, N.S., Klingelhofer, J., Grigorian, M.S., et al., The Metastasis-Associated Mts1 (S100A4) Protein Could Act as an Angiogenic Factor, Oncogene, 2001, vol. 20, pp. 4685-4695.
24. Olson, D.C. and Levine, A.J., The Properties of p53 Proteins Selected for the Loss of Suppression of Transformation, Cell Growth Diff., 1994, vol. 5, pp. 61-71.
25. Dittmer, D., Pati, S., Zambetti, G., et al., Gain-of-Function Mutations in p53, Nat. Genet., 1993, vol. 4, pp. 42-46.
26. Frazier, M.W., He, X., Wang, J., et al., Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain, Mol. Cell Biol., 1998, vol. 18, pp. 3735-3743.
27. Lanyi, A., Deb, D., Seymour, R.C., et al., "Gain of Function" Phenotype of Tumor-Derived Mutant p53 Requires the Oligomerization/Non-Sequence- Specific Nucleic Acid-Binding Domain, Oncogene, 1998, vol. 16, pp. 3169-3179.
28. Yang, X., Pater, A., and Tang, S.-C., Cloning and Characterization of the Human BAG-1 Gene Promoter: Upregulation by Tumor-Derived p53 Mutants, Oncogene, 1999, vol. 18, pp. 4546-4553.
29. Katayose, D., Gudas, J., Nguyen, H., et al., Cytotoxic Effects of Adenovirus-Mediated Wild-Type p53 Protein Expression in Normal and Tumor Mammary Epithelial Cells, Clin. Cancer Res., 1995, no. 1, pp. 889-897.
30. Nigro, J.M., Baker, S.J., Preisinger, A.C., et al., Mutations in the p53 Gene Occur in Diverse Human Tumor Types, Nature, 1989, vol. 342, pp. 705-708.
31. Kovach, J.S., Mcgovern, R.M., Cassady, J.D., et al., Direct Sequencing from Touch Preparations of Human Carcinomas: Analysis of p53 Mutations in Breast Carcinomas, J. Natl. Cancer Inst., 1991, vol. 83, pp. 1004-1009.
32. Elstner, E., Linker-Israeli, M., Said, J., et al., 20-Epi-Vitamin D3 Analogs: A Novel Class of Potent Inhibitors of Proliferation and Inducers of Differentiation of Human Breast Cancer Cell Lines, Cancer Res., 1995, vol. 55, pp. 2822-2830.
33. Wang, N.P., To, H., Lee, W.H., and Lee, E.Y., Tumor Suppressor Activity of RB and p53 Genes in Human Breast Carcinoma Cells, Oncogene, 1993, vol. 8, pp. 279-288.
34. Selivanova, G., lotsova, V., Okan, I., et al., Restoration of the Growth Suppression Function of Mutant p53 by a Synthetic Peptide Derived from the p53 C-Terminal Domain, Nat. Med., 1997, no. 3, pp. 632-638.
35. Romano, J.W., Ehrhart, J.C., Duthu, A., et al., Identification and Characterization of a p53 Gene Mutation in a Human Osteosarcoma Cell Line, Oncogene, 1989, vol. 4, pp. 1483-1488.
36. Casey, G., Lo-Hsueh, M., Lopez, M.E., et al., Growth Suppression of Human Breast Cancer Cells by the Introduction of a Wild-Type p53 Gene, Oncogene, 1991, vol. 6, pp. 1791-1797.
37. Cartel, A.L., Serfas, M.S., Cartel, M., et al., p21 (WAF1/CIP1) Expression Is Induced in Newly Nondividing Cells in Diverse Epithelia and during Differentiation of the Caco-2 Intestinal Cell Line, Exp. Cell Res., 1996, vol. 227, pp. 171-181.
38. Rodrigues, N.R., Roman, A., Smith, M.E., et al., p53 Mutations in Colorectal Cancer, Proc. Natl. Acad. Sci. USA, 1990, vol. 87, pp. 7555-7559.
39. Felix, C.A., Rappel, C.C., Mitsudomi, T., et al., Frequency and Diversity of p53 Mutations in Childhood Rhabdomyosarcoma, Cancer Res., 1992, vol. 52, pp. 2243-2247.
40. Isaacs, W.B., Carter, B.S., and Ewing, C.M., Wild-Type p53 Suppresses Growth of Human Prostate Cancer Cells Containing Mutant p53 Alleles, Cancer Res., 1991, vol. 51, pp. 4716-4620.
41. Kimura, M., Tagawa, M., Takenaga, K., et al., Inability to Induce the Alteration of Tumorigenicity and Chemosensitivity of p53-Null Human Pancreatic Carcinoma Cells after the Transduction of Wild-Type p53 Gene, Anticancer Res., 1997, vol. 17, pp. 879-883.
42. Cheng, Y.T., Li, Y.L., Wu, J.D., et al., Overexpression of MDM-2 mRNA and Mutation of the p53 Tumor Suppressor Gene in Bladder Carcinoma Cell Lines, Mol. Carcinogen., 1995, vol. 13, pp. 173-181.
43. Yaginuma, Y. and Westphal, H., Analysis of the p53 Gene in Human Uterine Carcinoma Cell Lines, Cancer Res., 1991, vol. 51, pp. 6506-6509.
44. O'Connell, K.A. and Edidin, M., A Mouse Lymphoid Endothelial Cell Line Immortalized by Simian Virus 40 Binds Lymphocytes and Retains Functional Characteristics of Normal Endothelial Cells, J. Immunol., 1990, vol. 144, pp. 521-525.
45. Wang, H., Mohammad, R.M., Werdell, J., and Shekhar, P.v.M., p53 and Protein Kinase C Independent Induction of Growth Arrest and Apoptosis by Bryostatin L in a Highly Metastatic Mammary Epithelial Cell Line: In Vitro versus In Vivo Activity, Int J. Mol. Med., 1998, no. 1, pp. 915-923.
46. Wadhwa, R., Takano, S., Robert, M., et al., Inactivation of Tumor Suppressor p53 by Mot-2, a Hsp70 Family Member, J. Biol. Chem., 1998, vol. 273, pp. 29 586-29 591.
47. Hayashi, S., Kano, E., Matsumoto, H., et al., Thermosensitivity, Incidence of Apoptosis and Accumulations of Hsp72 and p53 Proteins of Murine L Cells in Wild Type Status of p53 Gene, J. Exp. Clin. Cancer Res., 1999, vol. 18, pp. 181-189.